Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis

NCT02411708 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia, Sickle Cell

Interventions

DRUG: SANGUINATE
DRUG: Placebo

Sponsor

Prolong Pharmaceuticals